ASTEX PHARMACEUTICALS, INC Research and Development Expense
ASTEX PHARMACEUTICALS, INC reported Research and Development Expense of $18.15 million for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2013-08-09
- ASTEX PHARMACEUTICALS, INC research and development expense for the quarter ending 2013-06-30 was $18.15M, a 17.92% increase year-over-year.
- ASTEX PHARMACEUTICALS, INC research and development expense for the quarter ending 2013-03-31 was $17.86M, a 27.02% increase year-over-year.
- ASTEX PHARMACEUTICALS, INC research and development expense for the quarter ending 2012-12-31 was $17.33M, a 20.62% increase year-over-year.
- ASTEX PHARMACEUTICALS, INC research and development expense for the quarter ending 2012-09-30 was $13.63M, a 0.64% increase year-over-year.
- ASTEX PHARMACEUTICALS, INC research and development expense for fiscal 2012 was $60.42M, a 37.64% increase from fiscal 2011.
- ASTEX PHARMACEUTICALS, INC research and development expense for fiscal 2011 was $43.90M, a 54.59% increase from fiscal 2010.
- ASTEX PHARMACEUTICALS, INC research and development expense for fiscal 2010 was $28.39M, a 4.36% decline from fiscal 2009.
- ASTEX PHARMACEUTICALS, INC research and development expense for fiscal 2009 was $29.69M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2013-06-30 | $18.15M 10-Q · filed 2013-08-09 | $36.02M 10-Q · filed 2013-08-09 | $53.34M derived: sum of 3 quarters · filed 2013-08-09 | $66.98M derived: sum of 4 quarters · filed 2013-08-09 |
| 2013-03-31 | $17.86M 10-Q · filed 2013-05-10 | $35.19M derived: sum of 2 quarters · filed 2013-05-10 | $48.82M derived: sum of 3 quarters · filed 2013-05-10 | $64.22M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-12-31 | $17.33M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $30.96M derived: sum of 2 quarters · filed 2013-03-18 | $46.35M derived: sum of 3 quarters · filed 2013-08-09 | $60.42M 10-K · filed 2013-03-18 |
| 2012-09-30 | $13.63M 10-Q · filed 2012-11-09 | $29.03M derived: sum of 2 quarters · filed 2013-08-09 | $43.09M 10-Q · filed 2012-11-09 | $57.46M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-06-30 | $15.39M 10-Q · filed 2013-08-09 | $29.46M 10-Q · filed 2013-08-09 | $43.82M derived: sum of 3 quarters · filed 2013-08-09 | $57.37M derived: sum of 4 quarters · filed 2013-08-09 |
| 2012-03-31 | $14.06M 10-Q · filed 2013-05-10 | $28.43M derived: sum of 2 quarters · filed 2013-05-10 | $41.98M derived: sum of 3 quarters · filed 2013-05-10 | $49.97M derived: sum of 4 quarters · filed 2013-05-10 |
| 2011-12-31 | $14.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $27.91M derived: sum of 2 quarters · filed 2013-03-18 | $35.90M derived: sum of 3 quarters · filed 2013-03-18 | $43.90M 10-K · filed 2013-03-18 |
| 2011-09-30 | $13.55M 10-Q · filed 2012-11-09 | $21.54M derived: sum of 2 quarters · filed 2012-11-09 | $29.53M 10-Q · filed 2012-11-09 | $36.06M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $7.99M 10-Q · filed 2012-08-09 | $15.98M 10-Q · filed 2012-08-09 | $22.51M derived: sum of 3 quarters · filed 2013-03-18 | $29.67M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $7.99M 10-Q · filed 2012-05-10 | $14.52M derived: sum of 2 quarters · filed 2013-03-18 | $21.68M derived: sum of 3 quarters · filed 2013-03-18 | $28.95M derived: sum of 4 quarters · filed 2013-03-18 |
| 2010-12-31 | $6.53M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $13.69M derived: sum of 2 quarters · filed 2013-03-18 | $20.96M derived: sum of 3 quarters · filed 2013-03-18 | $28.39M 10-K · filed 2013-03-18 |
| 2010-09-30 | $7.16M 10-Q · filed 2011-11-09 | $14.43M derived: sum of 2 quarters · filed 2011-11-09 | $21.87M 10-Q · filed 2011-11-09 | |
| 2010-06-30 | $7.27M 10-Q · filed 2011-08-09 | $14.71M 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | $29.69M 10-K · filed 2012-03-15 |